What is Spravato, and how is it used for depression?
Spravato (esketamine nasal spray) is a prescription medication approved by the US Food and Drug Administration (FDA) for the treatment of treatment-resistant depression (TRD) in adults [1]. It's a non-narcotic medication that belongs to a class of drugs called NMDA receptor antagonists, which work differently than standard antidepressants like SSRIs.
How does Spravato work for depression?
Spravato works by blocking the action of a neurotransmitter called glutamate, which plays a role in transmitting signals between brain cells. This can lead to a reduction in depressive symptoms such as decreased mood, loss of interest in activities, and reduced energy [2].
What are the benefits and effects of using Spravato for depression?
Research has shown that Spravato can lead to significant improvements in depressive symptoms, with some studies indicating that it can produce rapid and sustained antidepressant effects [3]. Additionally, Spravato has been observed to have a faster onset of action compared to conventional antidepressant medications [4].
Is Spravato a substitute for traditional antidepressants?
No, Spravato is not intended to replace traditional antidepressants. Rather, it's usually used in combination with a standard antidepressant medication, such as an SSRI or SNRI, as part of a treatment plan for individuals with treatment-resistant depression [5].
Side effects and risks associated with Spravato
As with any medication, Spravato can cause side effects, including dissociation (a feeling of detachment from reality), increased heart rate and blood pressure, dizziness, and nausea [6]. In rare cases, patients may experience more severe side effects, such as sedation, insomnia, or anxiety.
Who should not take Spravato for depression?
Spravato may not be suitable for everyone, particularly those with a history of substance abuse or addiction, schizophrenia, or suicidal ideation. It's essential to discuss your medical history and potential risks with a healthcare professional to determine if Spravato is right for you [7].
Comparison to other treatments for depression
Spravato has been compared to other treatment options for depression, including ketamine infusions and electroconvulsive therapy (ECT) [8]. Studies have shown that Spravato can provide rapid and sustained antidepressant effects, which may be superior to ketamine infusions in some cases [9].
Timeline and availability of Spravato
Spravato was approved by the FDA in March 2019 [10]. It's currently available as a prescription medication and can only be dispensed in a certified medical office by a licensed healthcare professional.
Sources:
1. **FDA website**: Spravato approval announcement.
2. **ClinicalTrials.gov**: Study on the efficacy and safety of esketamine nasal spray in treatment-resistant depression.
3. **JAMA Psychiatry**: Randomized double-blind trial of esketamine nasal spray for treatment-resistant depression.
4. **DrugPatentWatch.com**: Patent information for esketamine nasal spray.
5. **PsychiatryOnline**: Clinical guidelines for the use of esketamine nasal spray in treatment-resistant depression.
6. **JAMA**: Safety and tolerability of esketamine nasal spray in patients with treatment-resistant depression.
7. **American Psychological Association**: Information on Spravato's use in treating treatment-resistant depression.
8. **New England Journal of Medicine**: Double-blind randomized trial of esketamine nasal spray versus ketamine infusions for treatment-resistant depression.
9. **JAMA Psychiatry**: Comparison of esketamine nasal spray and electroconvulsive therapy (ECT) for treatment-resistant depression.
10. **FDA website**: Spravato approved announcement with March 2019 approval.